Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match

Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match
To be or not to be in Medicare? That's the question facing NZX-listed Pacific Edge. (Image: Pacific Edge)
Rebecca Stevenson
The head of listed cancer diagnostics company Pacific Edge says its singular focus on the United States market is not a single point of failure. Pacific Edge’s share price has taken a hammering after it announced earlier this year it could lose access to the US Medicare system after Novitas – which administers Medicare – determined the Dunedin-based company’s products did not meet new thresholds for coverage under the US Social Security Act. On Monday, its shares were again buffeted by negative news when the US...

More Markets

NZX rallies past 13,000 points after RBNZ rate cut
Markets Market Close

NZX rallies past 13,000 points after RBNZ rate cut

The NZ sharemarket was up after results from Fletcher Building and Spark.

Major SkyCity investor ready to vote against directors
Markets

Major SkyCity investor ready to vote against directors

Allan Gray says an equity raise now would show the board to be poor stewards of capital.

Spark resets future dividend ratios, unveils new strategy
Markets

Spark resets future dividend ratios, unveils new strategy

Spark promises a return to basics and 'annuity-like' returns.

‘One of the most challenging periods in Spark’s history’
Markets

‘One of the most challenging periods in Spark’s history’

Spark has reported another big fall in profit, with reported net profit down 17.7% to $260 million, or a 33.6% fall to $227m, adjusting for asset sales and other one-offs.“The past year has been one of the most challenging periods in Spark’s history, as we navigated economic head...